Exploratory Borings Sample Clauses

Exploratory Borings. The geotechnical engineer will obtain borings at locations described by the Consultant for the proposed bridge structure and elsewhere along the West 347th Street road alignment. The Consultant will stake the location of the borings for Kleinfelder to use. It is understood that field adjustments may be required based on accessibility and/or conflicts. Kleinfelder will provide the Consultant with the necessary field information to tie out the new boring locations in the basemap if adjustments are required. One (1) boring will be located at each abutment and pier location. The abutment borings will be drilled from the existing roadway to a depth of approximately 15-feet into limestone and shale bedrock. The pier borings will be advance in the area of the existing bridge piers to a depth of approximately 30-feet into limestone and shale bedrock. Based on review of the available geologic information, the geotechnical engineer has assumed the coreable limestone bedrock will be 45-feet below existing grade at the abutment locations and 20-feet below grade at the piers.
View Source
Exploratory Borings. A Consultant field geologist or engineer will direct a subsurface investigation and implement the DEH- approved Workplan. The field staff will continuously log each boring in general accordance with the Unified Soil Classification System (USCS) (ASTM D-2487), and sample exploratory borings at seven (7) locations to depths up to approximately 25 feet for the collection of soil, soil vapor, and/or groundwater samples. A direct push drilling rig will be used to advance each exploratory boring to the desired depth and to assist with retrieving soil and groundwater samples. The direct push drilling rig will also be used to assist with the installation of the soil vapor probes. The direct push drilling rig will be equipped with a dual wall sampler that consists of an inner sampling barrel and an outer steel casing. The outer steel casing helps protect the integrity of the boring during sample collection and helps prevent cross contamination between different sampling intervals. The inner casing is fitted with an approximately 5-foot long acetate liner that retains soil as the casing is advanced. As the direct push drilling rig advances the dual wall sampler, in-situ soil is retained within the inner acetate liner. Once the sampler has been advanced approximately 5-feet, the acetate liner is retrieved leaving the core barrel in place and is then replaced with a new acetate liner for the next 5-foot interval. This procedure is repeated until the desired boring depth is achieved. An organic vapor meter (OVM) will be used to measure volatile vapors within the soil retained from each boring. For each 5-foot section of soil retrieved from an exploratory boring, a small hole will be drilled through the acetate liner at approximately 1-to-2-foot intervals, and the OVM probe will be inserted into the hole to record the volatile vapor concentrations. The subsurface material observations and OVM readings will be recorded on the boring logs. Soil samples will be collected for laboratory analysis from the five (5) locations where temporary soil vapor probes will be installed (discussed below). The soil samples will be collected from depths corresponding to the temporary vapor probe installation depth, which is anticipated to be approximately 5-feet and 15-feet at each location. Additional samples may be collected for laboratory analysis based on subsurface observations, OVM readings, and/or other signs of apparent contamination. The ten (10) soil samples will be analyzed for...
View Source
Exploratory Borings. To explore the subsurface conditions of the Phase 2 Project Site, the Consultant shall drill, log, and sample, at least, four (4) exploratory borings at the Phase 2 Project Site using conventional truck-mounted hollow-stem auger drilling equipment and 10 to 12 supplemental hand augers with hand augering equipment. The Consultant’s supplemental conventional borings shall extend to depths of approximately 20 to 40 feet in depth. The Consultant shall require that any hand augers utilized shall extend to depths of approximately five to 12 feet. The Consultant shall collect soil samples from the Consultant’s borings for visual classification and laboratory testing.
View Source
Exploratory Borings. To explore the subsurface conditions, The Consultant Team will drill, log and sample seven (7) exploratory borings at the site using conventional truck- mounted, hollow-stem auger drilling equipment and/or track-mounted, limited-access drilling equipment. Our conventional borings will extend to depths of approximately 10 to 30 feet below current site grades. The Consultant Team will collect soil samples from our borings for visual classification and laboratory testing. The approximate locations of our borings are shown on the attached Proposed Exploration Location Plan; final location of all explorations may be modified in the field as needed.
View Source

Related to Exploratory Borings

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Field The term “

  • Research Primary Investigator as part of a multi-site study (25 points) • Co-Investigator as part of a multi-site study (20 points) • Primary Investigator of a facility/unit based research study (15 points) • Co-Investigator of a facility/unit based research study (10 points) • Develops a unit specific research proposal (5 points) • Conducts a literature review as part of a research study (5 points)

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.